Nasal spray could deliver brain tumor treatment directly to Kids' tumors

NCT ID NCT06357377

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a nasal spray called NEO100 (a purified natural compound) in 12 children with certain aggressive brain tumors. The goal is to see if it's safe, find the best dose, and check if the drug reaches the tumor. Participants will receive increasing doses, and tumor samples will be tested for the drug if surgery is already planned.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

NEO100 (a purified form of perillyl alcohol, a natural compound)

What this could lead to

If it works, this could point toward a new way to deliver treatment directly to brain tumors through the nose, potentially reducing side effects.

What could go wrong

This is a very early, small Phase 1b trial with only 12 participants, focused on safety and dosing. It may not show any benefit, and side effects are unknown.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH GRADE GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

central nervous system cancer childhood brain stem neoplasm childhood choroid plexus carcinoma childhood neoplasm choroid plexus carcinoma diffuse glioma, H3 G34 mutant diffuse midline glioma, H3 K27-altered diffuse midline glioma, H3 K27M-mutant diffuse pediatric-type high-grade glioma, H3-wildtype and IDH-wildtype glioma malignant glioma Pinealoma pineoblastoma pineocytoma spinal cord neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••